MaxCyte, Inc. Editas Clinical and Commercial License Agreement (9473O)
07 October 2019 - 5:00PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9473O
MaxCyte, Inc.
07 October 2019
Editas Medicine and MaxCyte Announce Clinical and Commercial
License Agreement for Engineered Cell Medicines
CAMBRIDGE, Mass., and GAITHERSBURG, Md., October 7, 2019 -
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing
company, and MaxCyte, Inc. (LSE: MXCT, MXCS), the global cell-based
therapies and life sciences company, today announced a new clinical
and commercial license agreement. Editas Medicine will use
MaxCyte's Flow Electroporation(R) technology and ExPERT(TM)
instruments for the advancement of engineered cell medicines,
including EDIT-301, an experimental CRISPR medicine designed to
durably treat sickle cell disease and beta-thalassemia.
Under the terms of the agreement, Editas Medicine obtains
non-exclusive clinical and commercial use rights to MaxCyte's cell
engineering platform to develop up to five therapies including four
immuno-oncology therapies, and in return MaxCyte will receive
development and approval milestones and sales-based payments in
addition to other licensing fees.
"We look forward to working with MaxCyte and using its leading
technology to develop EDIT-301 as a best-in-class medicine for the
treatment of sickle cell disease and beta-thalassemia, and for up
to four engineered cell medicines to treat cancer," said Charles
Albright, Ph.D., Executive Vice President and Chief Scientific
Officer, Editas Medicine.
"We are excited to work with Editas Medicine as it is at the
forefront of developing engineered cell medicines that have the
potential to change the course of disease for many patients. This
agreement is also a significant business milestone for MaxCyte as
we continue to invest in our technology platform and help support
companies at the leading edge of cell therapy and gene editing to
develop medicines for patients in need," said Doug Doerfler,
President & CEO of MaxCyte, Inc.
MaxCyte's ExPERT instrument family represents the next
generation of leading, clinically validated, electroporation
technology for complex and scalable cellular engineering. By
delivering high transfection efficiency with enhanced
functionality, the ExPERT platform delivers the high-end
performance essential to enable the next wave of biological and
cellular therapeutics.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused
on translating the power and potential of the CRISPR/Cas9 and
CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a
robust pipeline of medicines for people living with serious
diseases around the world. Editas Medicine aims to discover,
develop, manufacture, and commercialize transformative, durable,
precision genomic medicines for a broad class of diseases. For the
latest information and scientific presentations, please visit
www.editasmedicine.com.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, including with all of
the top ten global biopharmaceutical companies. The Company now has
more than 80 partnered programme licenses in cell therapy with more
than 45 licensed for clinical use, including six commercial
licenses. Aggregate potential pre-commercial milestones from all
previously announced license deals total more than $450m. With its
robust delivery technology platform, MaxCyte helps its partners to
unlock the full potential of their products. For more information,
visit www.maxcyte.com.
Editas Medicine Forward-Looking Statements
This press release contains forward-looking statements and
information within the meaning of The Private Securities Litigation
Reform Act of 1995. The words "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "target," "should," "would," and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Editas Medicine may not actually achieve
the plans, intentions, or expectations disclosed in these
forward-looking statements, and you should not place undue reliance
on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in these forward-looking statements as a result of
various factors, including: uncertainties inherent in the
initiation and completion of preclinical studies and clinical
trials and clinical development of Editas Medicine's product
candidates; availability and timing of results from preclinical
studies and clinical trials; whether interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; expectations for regulatory
approvals to conduct trials or to market products and availability
of funding sufficient for Editas Medicine's foreseeable and
unforeseeable operating expenses and capital expenditure
requirements. These and other risks are described in greater detail
under the caption "Risk Factors" included in Editas Medicine's most
recent Quarterly Report on Form 10-Q, which is on file with the
Securities and Exchange Commission, and in other filings that
Editas Medicine may make with the Securities and Exchange
Commission in the future. Any forward-looking statements contained
in this press release speak only as of the date hereof, and Editas
Medicine expressly disclaims any obligation to update any
forward-looking statements, whether because of new information,
future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
###
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Editas Medicine
Media
Cristi Barnett +1 (617) 401-0113
------------------------------
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
------------------------------
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
------------------------------
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRCKODNPBDKAKK
(END) Dow Jones Newswires
October 07, 2019 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024